{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:52:20Z","timestamp":1762300340883,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Winning the Fight Foundation","award":["111990"],"award-info":[{"award-number":["111990"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive disease of neuronal degeneration in the motor cortex, brainstem, and spinal cord, resulting in impaired motor function and premature demise as a result of insufficient respiratory drive. ALS is associated with dysfunctions in neurons, neuroglia, muscle cells, energy metabolism, and glutamate balance. Currently, there is not a widely accepted, effective treatment for this condition. Prior work from our lab has demonstrated the efficacy of supplemental nutrition with the Deanna Protocol (DP). In the present study, we tested the effects of three different treatments in a mouse model of ALS. These treatments were the DP alone, a glutamate scavenging protocol (GSP) alone, and a combination of the two treatments. Outcome measures included body weight, food intake, behavioral assessments, neurological score, and lifespan. Compared to the control group, DP had a significantly slower decline in neurological score, strength, endurance, and coordination, with a trend toward increased lifespan despite a greater loss of weight. GSP had a significantly slower decline in neurological score, strength, endurance, and coordination, with a trend toward increased lifespan. DP+GSP had a significantly slower decline in neurological score with a trend toward increased lifespan, despite a greater loss of weight. While each of the treatment groups fared better than the control group, the combination of the DP+GSP was not better than either of the individual treatments. We conclude that the beneficial effects of the DP and the GSP in this ALS mouse model are distinct, and appear to offer no additional benefit when combined.<\/jats:p>","DOI":"10.3390\/nu15081821","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:19:54Z","timestamp":1681096794000},"page":"1821","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Glutamate Scavenging Protocol Combined with Deanna Protocol in SOD1-G93A Mouse Model of ALS"],"prefix":"10.3390","volume":"15","author":[{"given":"Christopher Q.","family":"Rogers","sequence":"first","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol S.","family":"Landon","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine M.","family":"DeBlasi","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Koutnik","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"},{"name":"Human Healthspan, Resilience and Performance, Florida Institute for Human and Machine Cognition, 40 S Alcaniz St, Pensacola, FL 32502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-823X","authenticated-orcid":false,"given":"Csilla","family":"Ari","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of South Florida, Tampa, FL 33612, USA"},{"name":"Ketone Technologies LLC, 12608 Forest Hills Dr, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-181X","authenticated-orcid":false,"given":"Dominic P.","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA"},{"name":"Ketone Technologies LLC, 12608 Forest Hills Dr, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_2","first-page":"95","article-title":"Exploring targets and therapies for amyotrophic lateral sclerosis: Current insights into dietary interventions","volume":"7","author":"Ngo","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ncl.2015.07.009","article-title":"Potential Environmental Factors in Amyotrophic Lateral Sclerosis","volume":"33","author":"Oskarsson","year":"2015","journal-title":"Neurol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/archneur.1990.00530050110021","article-title":"Immunologic reactivity against Borrelia burgdorferi in patients with motor neuron disease","volume":"47","author":"Halperin","year":"1990","journal-title":"Arch. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fnmol.2018.00063","article-title":"Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis?","volume":"11","author":"Xue","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ruffo, P., Perrone, B., and Conforti, F.L. (2022). SOD-1 Variants in Amyotrophic Lateral Sclerosis: Systematic Re-Evaluation According to ACMG-AMP Guidelines. Genes, 13.","DOI":"10.3390\/genes13030537"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.4103\/1673-5374.241445","article-title":"Animal models of amyotrophic lateral sclerosis: A comparison of model validity","volume":"13","author":"Morrice","year":"2018","journal-title":"Neural. Regen. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","article-title":"Unraveling the mechanisms involved in motor neuron degeneration in ALS","volume":"27","author":"Bruijn","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pansarasa, O., Bordoni, M., Diamanti, L., Sproviero, D., Gagliardi, S., and Cereda, C. (2018). SOD1 in Amyotrophic Lateral Sclerosis: \"Ambivalent\" Behavior Connected to the Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051345"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuron.2006.09.018","article-title":"ALS: A disease of motor neurons and their nonneuronal neighbors","volume":"52","author":"Boillee","year":"2006","journal-title":"Neuron"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1212\/WNL.47.4_Suppl_2.86S","article-title":"Clinical trials of riluzole in patients with ALS. ALS\/Riluzole Study Group-II","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1471-4159.1999.0720716.x","article-title":"Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons","volume":"72","author":"Koh","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10041","DOI":"10.3390\/ijms130810041","article-title":"Blood glutamate scavenging: Insight into neuroprotection","volume":"13","author":"Leibowitz","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1007\/s11064-012-0843-9","article-title":"Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naive rats","volume":"37","author":"Boyko","year":"2012","journal-title":"Neurochem. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e992","DOI":"10.1038\/cddis.2013.507","article-title":"Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia","volume":"5","author":"Sobrino","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s10637-012-9794-x","article-title":"Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas","volume":"30","author":"Ruban","year":"2012","journal-title":"Invest. New Drugs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000382034","article-title":"Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment","volume":"15","author":"Ruban","year":"2015","journal-title":"Neurodegener. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1474-9726.2009.00527.x","article-title":"Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK\/FOXO-dependent pathway","volume":"8","author":"Williams","year":"2009","journal-title":"Aging Cell"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ari, C., Poff, A.M., Held, H.E., Landon, C.S., Goldhagen, C.R., Mavromates, N., and D\u2019Agostino, D.P. (2014). Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103526"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11306-017-1183-1","article-title":"Biochemical alterations in Amyotrophic Lateral Sclerosis (ALS) Mouse Model resulted from the Deanna Protocol Supplement Complex","volume":"13","author":"Ari","year":"2017","journal-title":"Metabolomics"},{"key":"ref_22","first-page":"348","article-title":"Evaluation of Holistic Treatment for ALS Reveals Possible Mechanism and Therapeutic Potential","volume":"11","author":"Lavado","year":"2017","journal-title":"Int. J. Pharm. Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/17482960903545334","article-title":"Guidelines for preclinical animal research in ALS\/MND: A consensus meeting","volume":"11","author":"Ludolph","year":"2010","journal-title":"Amyotroph. Lateral. Scler."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.53.5.1059","article-title":"Nutritional status is a prognostic factor for survival in ALS patients","volume":"53","author":"Desport","year":"1999","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","article-title":"Energy metabolism in amyotrophic lateral sclerosis","volume":"10","author":"Dupuis","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"dmm040238","DOI":"10.1242\/dmm.040238","article-title":"Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model","volume":"12","author":"Crivello","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bbrc.2009.05.015","article-title":"Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice","volume":"384","author":"Lee","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1073\/pnas.85.22.8664","article-title":"Identification of arginine as a precursor of endothelium-derived relaxing factor","volume":"85","author":"Sakuma","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0735-1097(98)00375-1","article-title":"Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease","volume":"32","author":"Boger","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1203\/PDR.0b013e318176180e","article-title":"The arginine-creatine pathway is disturbed in children and adolescents with renal transplants","volume":"64","author":"Andrade","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00401-018-1835-x","article-title":"Energy metabolism in ALS: An underappreciated opportunity?","volume":"135","author":"Vandoorne","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11159","DOI":"10.1073\/pnas.0402026101","article-title":"Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model","volume":"101","author":"Dupuis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ajcn\/36.5.950","article-title":"Medium-chain triglycerides: An update","volume":"36","author":"Bach","year":"1982","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archneurol.2010.128","article-title":"Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis","volume":"67","author":"Crugnola","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1073\/pnas.95.15.8892","article-title":"Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects","volume":"95","author":"Matthews","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lucchetti, J., Marino, M., Papa, S., Tortarolo, M., Guiso, G., Pozzi, S., Bonetto, V., Caccia, S., Beghi, E., and Bendotti, C. (2013). A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9\/10 and does not benefit from exogenous administration of ubiquinol10. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069540"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/jnnp-2017-315574","article-title":"Fasciculation in amyotrophic lateral sclerosis: Origin and pathophysiological relevance","volume":"88","author":"Kiernan","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1527-3458.2001.tb00211.x","article-title":"Phenibut (beta-phenyl-GABA): A tranquilizer and nootropic drug","volume":"7","author":"Lapin","year":"2001","journal-title":"CNS Drug Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","article-title":"Glutamate receptors, neurotoxicity and neurodegeneration","volume":"460","author":"Lau","year":"2010","journal-title":"Pflugers. Arch."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00702-014-1181-7","article-title":"Brain to blood glutamate scavenging as a novel therapeutic modality: A review","volume":"121","author":"Boyko","year":"2014","journal-title":"J. Neural. Transm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/jcbfm.2013.186","article-title":"Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication","volume":"34","author":"Ruban","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/21678421.2013.788405","article-title":"ALS Untangled No. 20: The Deanna protocol","volume":"14","author":"Group","year":"2013","journal-title":"Amyotroph. Lateral. Scler. Frontotemporal. Degener."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1093\/hmg\/ddu371","article-title":"Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis","volume":"23","author":"Wilkins","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-4274(03)00114-0","article-title":"Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice","volume":"143","author":"Yamamoto","year":"2003","journal-title":"Toxicol. Lett."},{"key":"ref_47","first-page":"3408467","article-title":"The Antioxidative Function of Alpha-Ketoglutarate and Its Applications","volume":"2018","author":"Liu","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2015.078","article-title":"Alpha-Ketoglutarate: Physiological Functions and Applications","volume":"24","author":"Wu","year":"2016","journal-title":"Biomol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clnu.2011.06.004","article-title":"Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients","volume":"30","author":"Genton","year":"2011","journal-title":"Clin. Nutr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.2196\/ijmr.2463","article-title":"Severe loss of appetite in amyotrophic lateral sclerosis patients: Online self-assessment study","volume":"2","author":"Holm","year":"2013","journal-title":"Interact. J. Med. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/17482968.2010.482592","article-title":"A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS","volume":"11","author":"Jawaid","year":"2010","journal-title":"Amyotroph. Lateral. Scler."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.22114","article-title":"Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis","volume":"44","author":"Paganoni","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Lange, D.J., Voustianiouk, A., MacGrogan, D., Ho, L., Suh, J., Humala, N., Thiyagarajan, M., Wang, J., and Pasinetti, G.M. (2006). A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci., 7.","DOI":"10.1186\/1471-2202-7-29"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.coph.2009.03.007","article-title":"Neuromuscular junction destruction during amyotrophic lateral sclerosis: Insights from transgenic models","volume":"9","author":"Dupuis","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model","volume":"10","author":"Carrasco","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn2047","article-title":"Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis","volume":"11","author":"Yamanaka","year":"2008","journal-title":"Nat. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cmet.2008.09.002","article-title":"Skeletal muscle is a primary target of SOD1G93A-mediated toxicity","volume":"8","author":"Dobrowolny","year":"2008","journal-title":"Cell Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1083\/jcb.200407021","article-title":"Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model","volume":"168","author":"Dobrowolny","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: Treatment trials in the SOD1 mouse and in human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiol. Dis."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/8\/1821\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:59Z","timestamp":1760123579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/8\/1821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["nu15081821"],"URL":"https:\/\/doi.org\/10.3390\/nu15081821","relation":{},"ISSN":["2072-6643"],"issn-type":[{"type":"electronic","value":"2072-6643"}],"subject":[],"published":{"date-parts":[[2023,4,10]]}}}